Now showing items 1-10 of 18
Biosimilar competition: lessons from Europe
(Nature Reviews Drug Discovery, 2014-01-21)
Recent Trends in Brand-Name and Generic Drug Competition
(Journal of Medical Economics, 2013)
Updated trends in US brand-name and generic drug competition
(Journal of Medical Economics, 2016-09)
Does generic entry always increase consumer welfare?
(Food Drug Law J, 2012)
This article examines how the nature of competition between brands in a therapeutic category changes after generic entry and provide a framework for analyzing the effect of generic entry on consumer welfare that takes into ...
An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors
(International Journal of the Economics of Business, 2016-05-03)
© 2016 International Journal of the Economics of Business.Human blood plasma and its derivative therapies have been used therapeutically for more than 50 years, after first being widely used to treat injuries during World ...
Innovation in the pharmaceutical industry: New estimates of R&D costs.
(J Health Econ, 2016-05)
The research and development costs of 106 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug and biologics development. ...
The cost of drug development.
(N Engl J Med, 2015-05-14)
FDA in the Twenty-First Century
(FDA Regulation Of Biosimilars, 2015)
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
(Health Aff (Millwood), 2014-06)
In March 2010 Congress established an abbreviated Food and Drug Administration approval pathway for biosimilars-drugs that are very similar but not identical to a reference biological product and cost less. Because bringing ...